99 related articles for article (PubMed ID: 15054909)
1. High-dose brachytherapy for treating prostate cancer: nursing considerations.
Colella J; Scrofine S
Urol Nurs; 2004 Feb; 24(1):39-44, 52. PubMed ID: 15054909
[TBL] [Abstract][Full Text] [Related]
2. The role of urinary assessment scores in the nursing management of patients receiving prostate brachytherapy.
Abel LJ; Blatt HJ; Stipetich RL; Fuscardo JA; Dafoe-Lambie JC; Dorsey AT; Butler WM; Merrick GS
Clin J Oncol Nurs; 2000; 4(3):126-9. PubMed ID: 11235250
[TBL] [Abstract][Full Text] [Related]
3. Nursing management of patients receiving brachytherapy for early stage prostate cancer.
Abel LJ; Blatt HJ; Stipetich RL; Fuscardo JA; Zeroski D; Miller SE; Dorsey AT; Butler WM; Merrick GS
Clin J Oncol Nurs; 1999 Jan; 3(1):7-15. PubMed ID: 10232167
[TBL] [Abstract][Full Text] [Related]
4. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
5. Treatment outcomes and quality-of-life issues for patients treated with prostate brachytherapy.
Abel L; Dafoe-Lambie J; Butler WM; Merrick GS
Clin J Oncol Nurs; 2003; 7(1):48-54. PubMed ID: 12629934
[TBL] [Abstract][Full Text] [Related]
6. Nursing considerations in brachytherapy-related erectile dysfunction.
Stipetich R; Abel LJ; Anderson RL; Butler WM; Wallner KE; Merrick GS
Urol Nurs; 2005 Aug; 25(4):249-54; quiz 259. PubMed ID: 16225341
[TBL] [Abstract][Full Text] [Related]
7. Use of conformal high-dose rate brachytherapy for management of patients with prostate cancer: optimizing dose escalation.
Vicini FA; Kestin LL; Martinez AA
Tech Urol; 2000 Jun; 6(2):135-45. PubMed ID: 10798815
[TBL] [Abstract][Full Text] [Related]
8. Management of patients receiving transperineal palladium-103 prostate implants.
Cash JC; Dattoli MJ
Oncol Nurs Forum; 1997 Sep; 24(8):1361-7. PubMed ID: 9380591
[TBL] [Abstract][Full Text] [Related]
9. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
[TBL] [Abstract][Full Text] [Related]
10. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
[TBL] [Abstract][Full Text] [Related]
11. Factors affecting patient selection for prostate brachytherapy: what nurses should know.
Zeroski D; Abel L; Butler WM; Wallner K; Merrick GS
Clin J Oncol Nurs; 2005 Oct; 9(5):553-60. PubMed ID: 16235582
[TBL] [Abstract][Full Text] [Related]
12. Developing a high-dose-rate prostate brachytherapy program.
Waring J; Gosselin T
Clin J Oncol Nurs; 2010 Apr; 14(2):199-205. PubMed ID: 20350893
[TBL] [Abstract][Full Text] [Related]
13. Power against prostate cancer. Intensity-modulated radiation therapy and interstitial brachytherapy.
Cash JC
Adv Nurse Pract; 2006 Sep; 14(9):37-42. PubMed ID: 16972442
[No Abstract] [Full Text] [Related]
14. Conformal high dose rate iridium-192 boost brachytherapy in locally advanced prostate cancer: superior prostate-specific antigen response compared with external beam treatment.
Stromberg JS; Martinez AA; Horwitz EM; Gustafson GS; Gonzalez JA; Spencer WF; Brabbins DS; Dmuchowski CF; Hollander JB; Vicini FA
Cancer J Sci Am; 1997; 3(6):346-52. PubMed ID: 9403047
[TBL] [Abstract][Full Text] [Related]
15. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
[TBL] [Abstract][Full Text] [Related]
16. PSA spike after brachytherapy For localized prostate cancer.
Abel L; Zeroski D; Brammer S; Butler W; Wallner KE; Merrick GS
Urol Nurs; 2007 Dec; 27(6):507-10, 518; quiz 511. PubMed ID: 18217533
[TBL] [Abstract][Full Text] [Related]
17. Brachytherapy: a minimally invasive option for treating prostate cancer.
Stahlinski CR; Friedman FP; Finklestein S
Minim Invasive Surg Nurs; 1994; 8(3):106-9. PubMed ID: 7812389
[No Abstract] [Full Text] [Related]
18. Lack of benefit of pelvic radiation in prostate cancer patients with a high risk of positive pelvic lymph nodes treated with high-dose radiation.
Vargas CE; Galalae R; Demanes J; Harsolia A; Meldolesi E; Nürnberg N; Schour L; Martinez A
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1474-82. PubMed ID: 15964706
[TBL] [Abstract][Full Text] [Related]
19. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.
Vargas C; Martínez A; Galalae R; Demanes J; Harsolia A; Schour L; Nuernberg N; Gonzalez J
Prostate Cancer Prostatic Dis; 2006; 9(3):245-53. PubMed ID: 16786040
[TBL] [Abstract][Full Text] [Related]
20. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS
J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
